U.S. Corporate Tax Code is Unhealthy for Medical Innovation
April 11, 2016
The U.S. Treasury has just dropped 300-plus pages of tax regulations designed to blow up the merger between Pfizer and Allergan. It succeeded, but fails to address the real problem, writes NCPA Senior Fellow John R. Graham.
Browse more articles on Tax and Spending Issues